This document provides information on pharmaceutical intermediates and products from Ark Pharm, Inc. It lists categories including antivirals, antineoplastics, antipsychotics, antifungals, respiratory/pulmonary agents, and others. For each category, it provides the number of intermediates available and lists examples of drug targets and example drugs in clinical trials or recently approved. It also provides bibliographic references of Ark Pharm's publications and contact information.

1. Respiratory Tract/Pulmonary Agents
Antineoplastics
Antivirals
Antifungals
Antipsychotics
PHARMACEUTICAL INTERMEDIATES

2. J. Am. Chem. Soc., 2017, 139 (51), pp 18590–18597
J. Am. Chem. Soc., 2017, 139 (14), pp 5183–5193
J. Am. Chem. Soc., 2016, 138 (41), pp 13639–13646
Nano Energy 33 (2017) 350–355
Nature Communications 7, 12803 (2016)
Angew. Chem. Int. Ed. 2017, 56, 15698 –15702
ACS Catal., 2017, 7 (10), pp 6745–6756
Chem. Mater., 2013, 25 (1), pp 12–16
ACS Appl. Mater. Interfaces, 2017, 9 (42), pp 37254–37263
ACS Appl. Mater. Interfaces, 2016, 8 (49), pp 33423–33429
Macromolecules, 2017, 50 (11), pp 4180–4187
Biomacromolecules, 2016, 17 (9), pp 3016–3024
Polymer, 2016, 84 (1), 336-342
RSC Adv., 2017, 7, 21953–21961
…
Ark Pharm Products have been cited in more than 1,000
articles of famous academic journals like Nature, JACS, Angew...
Ark Pharm, Inc.
3860 N. Ventura Drive, Arlington Heights, IL 60004, USA
sales@arkpharmusa.com
+1-847-367-3680 +1-847-367-3681
www.arkpharmusa.com

3. * Status: Drug Targets: Cat. No.: CAS No.:www.arkpharmusa.com | +1-847-367-3680
Antivirals
(120+ Intermediates)
(5 Intermediates) (7 Intermediates)
54-42-2AK-35587
79887-10-8AK-48503
68858-20-8AK-46044 31618-90-3AK-90240
5451-40-1AK-26103
56-05-3AK-26984
(26 Intermediates) (29 Intermediates)
74844-91-0AK-44088
1184-88-9AK160916
20859-02-3AK-47550
13726-69-7AK-46634
62-23-7AK-77655
112970-44-2AK-45647
Valnivudine
Phase III Clinical Trial
DNA Polymerase
Amenamevir
2017 approval
Helicase-primase
Grazoprevir
2016 approval
NS3/4A
Faldaprevir
Phase III Clinical Trial
NS3/4A
Antivirals
(70+ Intermediates)
Antineoplastics
(12 Intermediates) (8 Intermediates)
446-32-2AK-25985
3473-63-0AK-76644
16499-57-3AK-24066 67567-26-4AK-37846
149806-06-4AK-25442
5773-80-8AK-86916
(11 Intermediates) (13 Intermediates)
830-79-5AK-49060
621-23-8AK112024
393-53-3AK-25903
2450-26-2AK119669
3167-50-8AK-17303
7357-67-7AK-36245
Dacomitinib
Phase III Clinical Trial
EGFR, ErbB2, ErbB4
Orteronel
Phase III Clinical Trial
CYP17A1
Riviciclib
Phase III Clinical Trial
CDK4, CDK9
Copanlisib
2017 approval
PI3Kα, PI3Kδ
Antineoplastics
(1700+ Intermediates)

4. * Status: Drug Targets: Cat. No.: CAS No.:www.arkpharmusa.com | +1-847-367-3680
Antipsychotics
(9 Intermediates) (10 Intermediates)
29976-53-2AK-39199
65376-05-8AK-79086
186204-35-3AK-67666
123-08-0AK-77323
18962-07-7AK-45922
767-00-0AK-44095
(8 Intermediates) (6 Intermediates)
1118-68-9AK-41194
22246-18-0AK-51661
6630-33-7AK-50022
70500-72-0AK-26280
57260-71-6AK-49934
5118-13-8AK-28145
Lumateperone
Phase III Clinical Trial
5-HT2A receptor,
Dopamine receptor
Pimavanserin
2016 approval
5-HT2A receptor
Aripiprazole Lauroxil
2015 approval
DRD2, 5-HT1A receptor,
5-HT2A receptor
Brexpiprazole
2015 approval
DRD2, 5-HT1A receptor,
5-HT2A receptor
Antipsychotics
(130+ Intermediates)
Antifungals
(22 Intermediates) (9 Intermediates)
32399-12-5AK-34687
399-94-0AK-76553
288-88-0AK111541
624-28-2AK-26195
106854-77-7AK-95103
73183-34-3AK-47583
(10 Intermediates) (7 Intermediates)
619-66-9AK-45367
94569-84-3AK-36950
288-88-0AK111541
184177-83-1AK-89728
619-44-3AK-45406
137234-74-3AK-47637
Isavuconazonium
2015 approval
CYP51
VT-1161
Phase II Clinical Trial
CYP51
Efinaconazole
2013 approval
CYP51
Anidulafungin
2006 approval
1→3-beta-glucan
synthase
Antifungals
(90+ Intermediates)

5. Genitourinary Agents
Respiratory Tract/Pulmonary Agents
* Status: Drug Targets: CAS No.:www.arkpharmusa.com | +1-847-367-3680
(50+ Intermediates)
(13 Intermediates) (4 Intermediates)
104-55-2AK-77787
139756-02-8AK-37706
4931-66-2AK-27009 54-12-6AK-44869
153-94-6AK-47467
124937-73-1AK-40881
(7 Intermediates) (7 Intermediates)
57-88-5AK105936
853-23-6AK307717
104-10-9AK-47701
104060-23-3AK-22085
94-02-0AK-72988
51019-43-3AK105882
Vibegron
Phase III Clinical Trial
ADRB3
Cizolirtine
Phase III Clinical Trial
CGRP
Prasterone
2016 approval
ER, AR
Flibanserin
2015 approval
5-HT1A receptor,
5-HT2A receptor, DRD4
(9 Intermediates) (6 Intermediates)
6971-51-3AK106250
102308-97-4AK-32682
29906-67-0AK-25728
90-14-2AK-26427
26447-85-8AK-27166
588-63-6AK-45305
(14 Intermediates) (22 Intermediates)
3430-17-9AK-23603
220210-56-0AK-48040
68119-31-3AK158449
867-13-0AK-98829
24078-21-5AK-45806
873055-57-3AK127988
Respiratory Tract/PulmonaryAgents
(120+ Intermediates)
Foropafant
Phase III Clinical Trial
PAF
Aclidinium Bromide
2012 approva
mAChR3
Lumacaftor
Phase III Clinical Trial
CFTR
Masilukast
Phase II Clinical Trial
CYSLTR1
Genitourinary Agents

6. * Status: Drug Targets: Cat. No.: CAS No.:www.arkpharmusa.com | +1-847-367-3680
Antidepressants
(8 Intermediates) (6 Intermediates)
6373-46-2AK-44726
14191-95-8AK-33252
1068-90-2AK-32785
15861-24-2AK-32216
90365-74-5AK-36817
1660-93-1AK-63875
(9 Intermediates) (7 Intermediates)
2398-37-0AK-76817
4133-34-0AK-25949
156-38-7AK101098
2969-81-5AK-41609
583-55-1AK-48364
97-51-8AK-48628
Befloxatone
Phase III Clinical Trial
MAO-A
Fluparoxan
Phase III Clinical Trial
ADRA2
Basimglurant
Phase II Clinical Trial
mGluR5
Vortioxetine
2013 approval
5-HT1B receptor,
5-HT1A receptor,
5-HT7 receptor,
5-HT1D receptor,
5-HT3 receptor,
5-HTT
Antidepressants
(500+ Intermediates)
Anticonvulsants
(8 Intermediates) (7 Intermediates)
75178-87-9AK112663
25137-01-3AK-41584
2969-81-5AK-41609
42843-94-7AK-35134
101623-69-2AK158831
217448-86-7AK142680
(8 Intermediates) (9 Intermediates)
29331-92-8AK122115
6066-82-6AK-94009
28721-09-7AK-93015
1072-97-5AK-26973
381233-96-1AK-28621
381233-75-6AK138249
Naluzotan
Phase II Clinical Trial
5-HT1A receptor
Gabapentin Enacarbil
2011 approval
CACNA2D2,
CACNA2D1
Brivaracetam
2016 approval
SV2A
Perampanel
2012 approval
AMPAR
Anticonvulsants
(60+ Intermediates)